Immunohistochemical evaluation of biological markers in mammary carcinoma in situ: Correlation with morphological features and recently proposed schemes for histological classification

Breast

Volumn 5, Issue 3, 1996, Pages 113-122

  Millis, R R ^a   Bobrow, L G ^a   Barnes, D M ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER SCREENING; CARCINOMA IN SITU; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MORPHOLOGY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030037187     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(96)90054-5     Document Type: Article

References (45)

1. Giri D E, Dundas SAC, Nottingham J F, Underwood JCE. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989; 15: 575-584.
2. Bur M E, Zimarowski M J, Schnitt S J, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992; 69: 1174-1181.
3. Barnes R, Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol 1990; 94: 533-537.
4. Wilbur D C, Barrows G H. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Mod Pathol 1993; 6: 114-120.
5. Pallis L, Wilking N, Cedermark B, Rutqvist L E, Skoog L. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res 1992; 12: 2113-2116.
6. Poller D N, Snead D R J, Roberts E C, et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 1993; 68: 156-161.
7. Bobrow L G, Happerfield L C, Gregory W M, Willis R R. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 1995; 17: 333-341.
8. Zafrani B, Leroyer A, Fourquet A et al. Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: Correlation with oestrogen and progesterone receptors, p53 and c-erbB-2 proteins and proliferative activity. Semin Diagn Pathol 1994; 11: 208-214.
9. Meyer J S. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat 1986; 7: 171-180.
10. Locker A P, Horrocks C, Gilmour A S et al. How cytometric and histological analysis of ductal carcinoma in situ of the breast. Br J Surg 1990; 77: 564-567.
11. Sampson S A, Kreipe H, Gillett C E et al. KiS1 - A novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma. J Pathol 1992; 168: 179-185.
12. Bobrow L G, Happerfield L C, Gregory W M, Springall R J, Millis R R. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 1994; 11: 199-207.
13. van der Vijver M J, Peterse J L, Mooi W J et al. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Eng J Med 1988; 319: 1239-1245.
14. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson B A. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma - a detailed morphological analysis. J Pathol 1990; 161: 7-14.
15. Bartkova J, Barnes D M, Millis R R, Gullick W J. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 1990; 21: 1164-1167.
16. Press M F, Hung G, Godolphin W, Slamon D J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771-2777.
17. Bobrow L G, Happerfield L C, Millis R R. Evaluation of antibodies to c-erbB-2. J Pathol 1994; 172 (supp): 126A.
18. Lodato R F, Maguire H C, Greene M I, Weiner D B, Livolsi V A. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990; 3: 449-454.
19. Somerville J E, Clarke L A, Biggart J D. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol 1992; 45: 16-20.
20. Schimmelpenning H, Eriksson E T, Pallis L, Skoog L, Cedermark B, Auer G U. Immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human mammary carcinoma in situ. Am J Clin Pathol 1992; 97: S48-S52.
21. Poller D N, Galea M, Pearson D et al. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Breast Cancer Res Treat 1991; 20: 3-10.
22. Evans J, Finder S E, Ellis I O et al. Correlations between the mammographie features of ductal carcinoma in situ (DCIS) and c-erbB-2 oncogene expression. Clin Radiol 1994; 49: 559-562.
23. De Potter C R, Foschini M P, Schelfhout A-M, Schroeter C A, Eusebi V. Immunohistochemical study of neu protein overexpression in clinging in situ duct carcinoma of the breast. Virchows Arch A 1993; 422: 375-380.
24. Walker R A, Dearing S J, Lane D P, Varley J M. Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 1991; 165: 203-211.
25. Poller D N, Roberts E C, Bell J A, Elston C W, Blarney R W, Ellis I O. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993; 24: 463-468.
26. Humphrey P A, Franquemont D W, Geary W A, Kerns B-J M, Iglehart J D, Marks J R. Immunodetection of p53 protein in noninvasive epithelial proliferative breast disease. Appl Immunohistochem 1994; 2: 22-28.
27. O'Malley F P, Vnencak-Jones C L, Dupont W D, Pari F, Manning S, Page D L. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest 1994; 71: 67-72.
28. Millis R R. Correlation of hormone receptors with pathological features in human breast cancer. Cancer 1980; 46: 2869-2871.
29. Benner S E, Clark G M, MoGuire W L. Steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer. Am J Med Sci 1988; 296: 59-66.
30. Howell A, Barnes D M, Harland R N L et al. Steroid hormone receptors and survival after first relapse in breast cancer. Lancet 1984; i: 588-591.
31. Baak J P A, van Dop H, Kurver P H J et al. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56: 374-382.
32. Meyer J S, Hixon B. Advanced stage and early relapse of breast carcinomas associated with high thymidine labelling indices. Cancer Res 1979; 39: 225-235.
33. O'Reilly S M, Camplejohn R S, Barnes D M et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 1990; 61: 671-674.
34. Sahin A A, Ro J, Ro J Y et al. Ki67 immunostaining in node negative stage I and II breast cancer: significant correlation with prognosis. Cancer 1991; 68: 549-557.
35. Slamon D J, Godolphin W, Jones L A et al. Expression of c-erbB-2 oncoprotein: a prognostic marker in human breast cancer. Cancer Res 1989; 49: 2087-2091.
36. Lovekin C, Ellis I O, Locker A et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63: 439-443.
37. Allred D C, Clark G M, Elledge R et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome of node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206.
38. Barnes D M, Dublin E A, Fisher C J, Levison D A, Millis R R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993; 24: 469-476.
39. Lagios M D, Margolin F R, Westdahl P R, Rose M R. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63: 618-624.
40. Lagios M D. Duct carcinoma in situ: pathology and treatment. Surg Clin North Am 1990; 70: 853-871.
41. Solin L J, Yeh I T, Kurtz J et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast with breast conserving surgery and definitive irradiation - correlation of pathological parameters with outcome of treatment. Cancer 1993; 71: 2532-2542.
42. Bellamy C O C, McDonald C, Salter D M, Chetty U, Anderson T J. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993; 24: 16-23.
43. Poller D N, Silverstein M J, Galea M et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification. Association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 1994; 7: 257-262.
44. Holland R, Peterse J L, Millis R R et al. Ductal carcinoma in situ: A proposal for a new classification. Semin Diagn Pathol 1994; 11: 167-180.
45. Stratton M R, Collins N, Lakhani S R, et al. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995; 175: 195-201.